Bypass patency was assessed by digital subtraction angiography, c

Bypass patency was assessed by digital subtraction angiography, computed tomographic angiography, and/or Doppler ultrasound. The modified Rankin Scale (mRS) was assigned for clinical grading at the last follow-up consultation.

RESULTS: The main indication for arterial

pedicle bypass surgery was internal carotid artery occlusion (79 cases); for vein bypass surgery, it was giant aneurysms (61 cases). Procedure-related complications due to surgery Go6983 concentration occurred in 3 cases (1.7%; 95% CI: 0.4-5.1%) of arterial pedicle bypass surgery and 12 cases (7.9%; 95% CI: 4.5-13.4%) of vein bypass surgery. The patency rate at 6 weeks was 98% (95% CI: 95.0-99.7%) for arterial pedicle bypass and 93% (95% CI: 87.4-96%) for vein bypass, with almost all graft AG-120 manufacturer failures occurring within the first week following surgery. Beyond the first week, bypass patency was similar for both groups, with both arterial pedicle grafts and vein bypass grafts that were patent at 1 week having a long-term patency of 99%. There was no statistically

significant difference in early, late, and overall patency between the 2 bypass groups.

CONCLUSION: The surgical complication rate was greater for vein bypass. Both arterial pedicle and vein bypass have good long-term patency.”
“BACKGROUND: Arteriovenous malformations (AVM) with associated aneurysms (AA) increase the risk of hemorrhage in adults. Associated aneurysms are thought to develop over time, and the incidence in children, therefore, has been thought to be minimal, although this has not yet been studied.

OBJECTIVE: To define the incidence and morbidity of AA in children and to assess the results of our treatment strategy.

METHODS: Patients younger than 18 years of age with pial AVM seen from 2000 to 2009 were reviewed. Demographics, presentation, hemorrhage, AAs, treatment method,

and outcome were analyzed.

RESULTS: Of 144 patients with AVM, 30 were younger than 18 years of age. AA was identified in 5 of 30 children (16.7%) and 33 of 114 adults (28.9%; P = .25). Mean AZD9291 research buy age at presentation in children was 11.67 years (range, 6 months to 17 years), and mean follow-up was 28.8 months (range, 1-75 months). Hemorrhage at presentation was seen in 80% of patients with AA and 72% with AVM alone. Emergent therapy was required in 60% of patients with AA and 40% with AVM alone (P = .63). Time to treatment was 4.3 days with AA and 27.3 days without (P = .42). There was no difference in outcome between patients with AA and those with AVM alone.

CONCLUSION: The incidence of pediatric AA was higher in our series than projected in the current literature. Time to treatment was shorter in children with AA compared with those with AVM alone, although there was no difference in clinical outcome. Although hemorrhage rates were similar, emergent therapy was required more often in patients with AA.

Comments are closed.